Squarepoint
PRQR icon

Squarepoint’s ProQR Therapeutics PRQR Stock Holding History

Squarepoint’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$51.1K Buy
+31,518
New +$51.7K ﹤0.01% 4139
2025
Q2 		– Sell
-112,463
Closed -$150K – 4946
2025
Q1 		$150K Buy
112,463
+29,349
+35% +$62.5K ﹤0.01% 4108
2024
Q4 		$220K Buy
83,114
+11,623
+16% +$36.9K ﹤0.01% 4394
2024
Q3 		$130K Sell
71,491
-13,242
-16% -$24.9K ﹤0.01% 3812
2024
Q2 		$141K Sell
84,733
-67,769
-44% -$132K ﹤0.01% 3737
2024
Q1 		$346K Buy
152,502
+24,328
+19% +$52K ﹤0.01% 3297
2023
Q4 		$254K Sell
128,174
-4,204
-3% -$6.46K ﹤0.01% 3459
2023
Q3 		$172K Sell
132,378
-1,764
-1% -$2.77K ﹤0.01% 3460
2023
Q2 		$217K Buy
+134,142
New +$262K ﹤0.01% 3172
2022
Q2 		– Sell
-49,878
Closed -$45K – 3265
2022
Q1 		$45K Buy
+49,878
New +$167K ﹤0.01% 2680
2021
Q4 		– Sell
-18,049
Closed -$151K – 3452
2021
Q3 		$151K Buy
+18,049
New +$118K ﹤0.01% 2591
2021
Q2 		– Sell
-75,196
Closed -$497K – 3598
2021
Q1 		$497K Buy
75,196
+55,391
+280% +$283K ﹤0.01% 2026
2020
Q4 		$83K Buy
+19,805
New +$83.6K ﹤0.01% 2746
2019
Q1 		– Sell
-10,700
Closed -$169K – 2379
2018
Q4 		$169K Buy
+10,700
New +$196K ﹤0.01% 1731

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Squarepoint's PRQR Position: Q1 2026 in Review

Squarepoint opened a new position in ProQR Therapeutics (PRQR) in Q1 2026: 31,518 shares worth $51.1K. The stake represents ﹤0.01% of the portfolio and ranks #4139 among its holdings. This is a return to the name: Squarepoint previously reported a position in PRQR as recently as Q1 2025.

Squarepoint first reported a position in PRQR in Q4 2018 and has held it in 14 quarters since. The position peaked at $497K in Q1 2021. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Squarepoint held 31,518 shares of ProQR Therapeutics worth $51.1K as of Q1 2026.
  • ProQR Therapeutics was a new Squarepoint position in Q1 2026.
  • ProQR Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4139 holding.
  • Squarepoint first reported a position in ProQR Therapeutics in Q4 2018 and has held it in 14 quarters since.
  • Squarepoint's ProQR Therapeutics position peaked at $497K in Q1 2021.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.